Internship
Confirmed live in the last 24 hours
Develops RNAi-based therapies for diseases
$22Hourly
Pasadena, CA, USA
You match the following Arrowhead Pharmaceuticals's candidate preferences
Employers are more likely to interview you if you match these preferences:
Arrowhead Pharmaceuticals develops medicines that treat severe diseases by targeting and silencing specific genes using RNA interference (RNAi). This method reduces gene expression, allowing for significant and lasting effects on conditions like cystic fibrosis and hepatitis B. The company stands out by focusing exclusively on RNAi-based therapies, addressing unmet medical needs in the biotechnology market. Their goal is to provide new treatment options for diseases with limited or no effective therapies.
Company Size
501-1,000
Company Stage
IPO
Total Funding
$4.7M
Headquarters
Pasadena, California
Founded
2004
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
Paid Vacation
Paid Sick Leave
Recently, Arrowhead Pharmaceuticals and Sarepta Therapeutics signed a global licensing and collaboration agreement to develop clinical and preclinical programmes.
Sarepta Therapeutics is putting massive biobucks on the line to work on RNA drugs with Arrowhead, paying out $500 million upfront to find new treatments for rare genetic diseases of the muscle, central nervous system and lung.
Arrowhead Pharmaceuticals unveiled a new RNAi-based obesity program on Wednesday that it believes could be "gentler" than currently available GLP-1 products...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has entered into a strategic financing agreement with Sixth Street for signific
Arrowhead Pharmaceuticals (NASDAQ:ARWR) receives "buy" Rating from Chardan Capital.